Description
Developer of therapies designed to offer treatment for neurological disorders. The company's therapies have developed a selective thyromimetic agent for the treatment of X-linked adrenoleukodystrophy, enabling X-ALD patients to get treatment for their rare genetic disease.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Out of Business | 01-Nov-2018 | 000.00 | Completed | Out of Business | ||
1. Early Stage VC (Series A) | 25-May-2017 | 000.00 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | 00,000,000 | 00.000000 | 00.00 | 00 | 00 | 00 | 00 | 00.000 |
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
aTyr Pharma | Formerly VC-backed | San Diego, CA | 00 | 00000 | 00000000 | 00000 |
000000 00000000000 | Formerly VC-backed | Burlingame, CA | 00 | 00000 | 000000 - 000 | 00000 |
000000 00000000000 | Formerly VC-backed | San Diego, CA | 00 | 00000 | 000000 - 000 | 00000 |
000000000 000000 | Venture Capital-Backed | Boston, MA | 00 | 00000 | 0000000000 0 | 00000 |
000000000 | Formerly VC-backed | South San Francisco, CA | 00 | 000.00 | 00000000 | 000.00 |